Show simple item record

dc.contributor.authorDe Giorgi, Riccardo
dc.contributor.authorDe Cates, Angharad N
dc.date.accessioned2021-03-31T15:45:05Z
dc.date.available2021-03-31T15:45:05Z
dc.date.issued2020-10
dc.identifier.citationDe Cates, A., & De Giorgi, R. (2020). Adjunctive benzodiazepines in depression: A clinical dilemma with no recent answers from research. BJPsych Advances, 26(6), 321-326.en
dc.identifier.urihttps://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/760
dc.descriptionThe article attached to this record is the Author(s) pre-/post- print version only. NOTE: this is not the version published in BJPsych Advances. Minor changes may have been made for publication. Eligible users can access the full text via NHS OpenAthens (login required)
dc.description.abstractComorbid anxiety symptoms are common in depression, and adding benzodiazepines to antidepressant treatment may seem a rational clinical solution. Benzodiazepines also have potential to reduce the initial anxiety that may be caused by early antidepressant treatment (owing to their inhibitory effect via GABAA receptor binding). This month's Cochrane Corner review examines the evidence behind combination treatment versus antidepressants alone in major depressive disorder, in terms of both the clinical and neuroscientific context. The review provides evidence that, in the first 4 weeks of treatment, additional medication with a benzodiazepine may lead to greater improvements than antidepressant alone on ratings of severity, response rates and remission rates for depression, but not on measures of anxietyen
dc.description.urihttps://doi.org/10.1192/bja.2020.17en
dc.language.isoenen
dc.subjectDepressive Disordersen
dc.titleAntidepressants plus benzodiazepines in major depressive disorder: a clinical dilemma with no recent answers from researchen
dc.typePrePrinten
dc.contributor.disciplineMedical Traineeen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record